CD8A and neoplasm: Interestingly, CD8+ T cells compensatory upregulate the Gln transporter ATB+/SLC6A14 to maintain their Gln uptake requirement after treatment with V-9302, but this phenomenon was not observed in tumor cells.284 In addition, PD-L1 upregulation was observed in tumor cells after V-9302 treatment, and the combination of V-9302 and anti-PD-1 antibody showed greater anti-tumor efficacy than either drug alone.291,292